Addex Therapeutics Ltd
ADXN
$6.07
$0.132.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.50K | 38.90K | 63.90K | 191.40K | 458.40K |
| Total Other Revenue | 167.40K | 147.90K | 128.30K | 84.20K | 6.80K |
| Total Revenue | 204.90K | 186.80K | 192.30K | 275.70K | 465.40K |
| Cost of Revenue | 809.30K | 817.60K | 768.60K | 859.60K | 966.40K |
| Gross Profit | -604.40K | -630.80K | -576.40K | -584.10K | -501.20K |
| SG&A Expenses | 2.80M | 2.31M | 2.21M | 2.31M | 2.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.61M | 3.13M | 2.98M | 3.17M | 3.59M |
| Operating Income | -3.41M | -2.94M | -2.79M | -2.90M | -3.12M |
| Income Before Tax | -8.28M | -7.34M | -7.13M | -6.37M | -5.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.28 | -7.34 | -7.13 | -6.37 | -5.57 |
| Earnings from Discontinued Operations | 138.40K | 124.60K | 121.80K | 15.83M | 13.14M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.14M | -7.22M | -7.01M | 9.46M | 7.57M |
| EBIT | -3.41M | -2.94M | -2.79M | -2.90M | -3.12M |
| EBITDA | -3.40M | -2.91M | -2.70M | -2.68M | -2.91M |
| EPS Basic | -0.08 | -0.07 | -0.07 | 0.10 | 0.08 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.05 | -0.04 | -0.04 |
| EPS Diluted | -0.08 | -0.07 | -0.07 | 0.10 | 0.08 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.05 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 429.43M | 409.88M | 395.50M | 393.29M | 392.48M |
| Average Diluted Shares Outstanding | 429.43M | 409.88M | 395.50M | 393.29M | 392.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |